Literature DB >> 2873525

A cobalamin metabolic defect with homocystinuria, methylmalonic aciduria and macrocytic anemia.

R J Mamlok, J N Isenberg, D K Rassin, K Norcross, H H Tallan.   

Abstract

We have identified a patient with methylmalonic aciduria and homocystinuria due to a defect in cobalamin metabolism of the cb1C type mutant. At the time of admission at eight months of age the patient was malnourished, hypotonic and had macrocytic anemia. Neonatal screening for hypermethioninemia associated with homocystinuria had been normal. Serum vitamin B12 was markedly increased and folate concentration was above normal, as were urinary homocystine and methylmalonic acid. The patient had abnormal brain stem auditory and visual evoked potentials. Fibroblast activity of N5-methyltetrahydrofolate: homocysteine methyltransferase was reduced to approximately 10% of concurrent controls. A course of therapy with hydroxocobalamin resulted in a 90% reduction in excretion of methylmalonic acid and normalization of the evoked potentials. These studies support the efficacy of hydroxocobalamin therapy in this disease, suggest that methylmalonic acid may be the most appropriate metabolite to monitor for therapeutic response, and in importance of electrophysiologic studies in character in objectively monitoring the response to treatment metabolic disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873525     DOI: 10.1055/s-2008-1052508

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Biochemical diagnosis and outcome of 2 years treatment in a patient with combined methylmalonic aciduria and homocystinuria.

Authors:  C Bellini; R Cerone; W Bonacci; U Caruso; C P Magliano; G Serra; B Fowler; C Romano
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

Review 2.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

4.  Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC).

Authors:  D S Rosenblatt; A L Aspler; M I Shevell; B A Pletcher; W A Fenton; M R Seashore
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

5.  Methylmalonic aciduria with homocystinuria: biochemical studies, treatment, and clinical course of a Cbl-C patient.

Authors:  A Ribes; P Briones; M A Vilaseca; M Lluch; M Rodes; A Maya; J Campistol; P Pascual; T Suormala; R Baumgartner
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

6.  The vitamin B12 processing enzyme, mmachc, is essential for zebrafish survival, growth and retinal morphology.

Authors:  Jennifer L Sloan; Nathan P Achilly; Madeline L Arnold; Jerrel L Catlett; Trevor Blake; Kevin Bishop; Marypat Jones; Ursula Harper; Milton A English; Stacie Anderson; Niraj S Trivedi; Abdel Elkahloun; Victoria Hoffmann; Brian P Brooks; Raman Sood; Charles P Venditti
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

7.  Clinical presentation and outcome in a series of 88 patients with the cblC defect.

Authors:  Sabine Fischer; Martina Huemer; Matthias Baumgartner; Federica Deodato; Diana Ballhausen; Avihu Boneh; Alberto B Burlina; Roberto Cerone; Paula Garcia; Gülden Gökçay; Stephanie Grünewald; Johannes Häberle; Jaak Jaeken; David Ketteridge; Martin Lindner; Hanna Mandel; Diego Martinelli; Esmeralda G Martins; Karl O Schwab; Sarah C Gruenert; Bernd C Schwahn; László Sztriha; Maren Tomaske; Friedrich Trefz; Laura Vilarinho; David S Rosenblatt; Brian Fowler; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2014-03-06       Impact factor: 4.982

8.  Cobalamin C Disease: Cognitive Dysfunction, Spastic Ataxic Paraparesis, and Cerebral White Matter Hyperintensities in a Genetic but Easily Treatable Cause!

Authors:  Ayush Agarwal; Vibhor Upadhyay; Anu Gupta; Ajay Garg; Venugopalan Y Vishnu; Roopa Rajan; Mamta Bhushan Singh; Rohit Bhatia; M V Padma Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2021-02-10       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.